Xention Limited

Japan Tobacco Inc.

Trigen Gmbh

David John Madge

Derek Edward John

John Ford

Basil Hartzoulakis

Mushtaq Mulla

Richard John Hamlyn

John Atherall

Nicholas John Palmer

Sasha Louise Garrett

Simon James Jones

Simon Mark Jones

Oliver Gareth Dugdale

John Joseph Deadman

Simon David Edwards

Mark Bushfield

Helen Jane Payne

Sanjay Kumar Kakkar

Anthony James Kennedy

Sophie Marie Combe-Marzelle

Mark Dolman

Derek Roland Pollard

Brad Sherborne

Edward Benedict Stevens

Jamie David Knight

Lindsay Brown

Richard Blunt

Suresh Babubhai Chahwala

Oliver Vimpany Arnold Boucher

Fiona Chan

Derek John

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein X, R, R, R, R, and Rare defined as set forth in the specification. The compounds are useful as potassium ion channel inhibitors.

Potassium channel blockers

The present invention provides compounds of formula (I): (Formula (I); wherein A, R, R, R, V, X, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by K3.1 and/or K3.4 or any heteromultimers thereof, or that require inhibition of K3.1 and/or K3.4 or any heteromultimers thereof.

Thieno-pyrimidines, useful as potassium channel inhibitors

The present invention provides thienopyridine compounds which are potassium channel inhibitors. In another embodiment, the invention provides pharmaceutical compositions comprising thienopyridines. In another embodiment, the invention provides methods of using thienopyridines in the treatment or prevention of cancer, arrhythmias, autoimmune diseases and inflammatory diseases, including gastric cancer, atrial fibrillation, type-2 diabetes mellitus, rheumatoid arthritis, type-1 diabetes, inflammatory bowel disorder and demyelinating disorders such as multiple sclerosis.

Thieno[3,2-c]pyridine potassium channel inhibitors

Compounds

A compound of formula (I)  Or its salts or pharmaceutically acceptable derivatives thereof wherein; 

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof, wherein R, R, R, R, R, X, and j are defined herein. The compounds are useful as potassium ion channel inhibitors.

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives wherein R, R, R, X, and A are defined herein. The compounds are useful as potassium ion channel inhibitors.

The invention provides compounds of the formula:  These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.

Thieno[2 3-b]pyridines as potassium channel inhibitors

This invention relates to novel compound of formula (I) or pharmaceutically acceptable salts thereof. The invention is also directed to the uses of compounds having formula (I) in the treatment or prevention of diseases or disorders which requires potassium channel inhibition to an animal, mammal or human in need thereof. The invention is also directed to the use of compounds having formula (I) in the treatment or prevention of arrhythmia to an animal, mammal or human in need thereof.

Substituted thieno[2,3-d]pyrimidines as potassium channel inhibitors

The invention provides compounds of the formula: wherein These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.

Thieno[2,3-B] pyridines as potassium channel inhibitors

Furanopyrimidine compounds as potassium ion channel inhibitors

Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.

Multivalent metal salts of boronic acids

Growing community of inventors

Cambridgeshire, United Kingdom

David John Madge